SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-040541
Filing Date
2019-11-06
Accepted
2019-11-05 18:24:21
Documents
70
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rare-10q_20190930.htm   iXBRL 10-Q 2989684
2 EX-31.1 rare-ex311_8.htm EX-31.1 17457
3 EX-31.2 rare-ex312_7.htm EX-31.2 17456
4 EX-32.1 rare-ex321_12.htm EX-32.1 10889
5 GRAPHIC gv2ltt322nv0000001.jpg GRAPHIC 41778
  Complete submission text file 0001564590-19-040541.txt   8924896

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA rare-20190930.xsd EX-101.SCH 54447
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rare-20190930_cal.xml EX-101.CAL 58215
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rare-20190930_def.xml EX-101.DEF 144090
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE rare-20190930_lab.xml EX-101.LAB 363987
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rare-20190930_pre.xml EX-101.PRE 284785
30 EXTRACTED XBRL INSTANCE DOCUMENT rare-10q_20190930_htm.xml XML 1699119
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36276 | Film No.: 191194614
SIC: 2834 Pharmaceutical Preparations